US FDA OK's Gilead's Truvada as 1st HIV prophylaxis pill
This article was originally published in Scrip
Executive Summary
Gilead Sciences won approval to expand the indication for Truvada (emtricitabine/tenofovir disoproxil fumarate) in the US as the first agent prescribed as a pre-exposure prophylaxis (PrEP) therapy to reduce the risk of HIV-1 among uninfected adults at high risk of acquiring the infection – gaining the US FDA's nod amid controversy.